An Open Label Phase II Study on the Use of Panobinostat in Combination with Bortezomib and Dexamethasone as Induction in Multiple Myeloma Patients Candidate to High-Dose Therapy [Studio di fase II sull'uso di panobinostat associato a bortezomib e desametasone come terapia di induzione in pazienti con mieloma multiplo candidati ad una terapia ad alte dosi]
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2016
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- 23 May 2013 Status changed from suspended to discontinued as reported by European Clinical Trials Database.
- 02 Mar 2013 Status changed from recruiting to suspended as reported by European Clinical Trials Database.
- 04 Jan 2013 Planned End Date (15 Oct 2018) added as reported by European Clinical Trials Database.